Targeting the Neddylation Pathway to Suppress the Growth of Prostate Cancer Cells: Therapeutic Implication for the Men’s Cancer

<table>MLN4924 induced accumulation of CRLs substrates and triggered DNA damage in prostate cancer cells. Subconfluent cells were treated with MLN4924 (0, 0.1, 0.33, 1.0 <i>μ</i>M) for 48 hours, followed by IB analysis using antibodies against p21, p27, p-I<i>κ</i>B<i>α</i>, t-I<i>κ</i>B<i>α</i>, CDT1, ORC1, p-H2AX, and t-H2AX with GAPDH as a loading control.</table>

BioMed Research International

fig3

Figure 3

Figure 3: Targeting the Neddylation Pathway to Suppress the Growth of Prostate Cancer Cells: Therapeutic Implication for the Men’s Cancer 